Update on systemic therapy for clear cell renal cell carcinoma

被引：1
|
作者：
Muehlmann, Josef [1 ]
机构：
[1] Hosp Barmherzige Bruder Bros Mercy, Dept Internal Med, Kajetanerpl 1, A-5020 Salzburg, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 01期
关键词：
Adjuvant therapy; Belzutifan; First-line therapy; Second-line therapy; Pembrolizumab; PHASE-III; COMBINATION; RISK;
D O I：
10.1007/s12254-022-00867-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories. Currently, combination therapies represent the standard-of-care in the first-line setting of clear cell RCC in almost all cases. In this short review article, the most recent therapeutic advances in early and advanced stage of clear cell RCC are summarized.
引用
收藏
页码：38 / 41
页数：4
相关论文
共 50 条
  • [41] DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Ged, Yasser
    Chaim, Joshua L.
    DiNatale, Renzo G.
    Knezevic, Andrea
    Kotecha, Ritesh R.
    Carlo, Maria, I
    Lee, Chung-Han
    Foster, Ashley
    Feldman, Darren R.
    Teo, Min Yuen
    Iyer, Gopakumar
    Chan, Timothy
    Patil, Sujata
    Motzer, Robert J.
    Hakimi, A. Ari
    Voss, Martin H.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [42] Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Takagi, Toshio
    Yoshida, Kazuhiko
    Kondo, Tsunenori
    Tanabe, Kazunari
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (05) : 605 - 607
  • [43] Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma
    Sofia Canete-Portillo
    Maria del Carmen Rodriguez Pena
    Dezhi Wang
    Diego F. Sanchez
    George J. Netto
    Cristina Magi-Galluzzi
    [J]. Virchows Archiv, 2021, 479 : 1187 - 1196
  • [44] Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy
    Urman, Danielle
    Deshler, Leah
    Weise, Nicole
    Shabaik, Ahmed
    Derweesh, Ithaar
    Bagrodia, Aditya
    Rose, Brent
    Herchenhorn, Daniel
    McKay, Rana R.
    [J]. CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : 660 - 668.e1
  • [45] Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions
    Chowdhury, Simon
    Matrana, Marc R.
    Tsang, Christopher
    Atkinson, Bradley
    Choueiri, Toni K.
    Tannir, Nizar M.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) : 853 - +
  • [46] Promising systemic therapy for renal cell carcinoma
    Cooney M.M.
    Remick S.C.
    Vogelzang N.J.
    [J]. Current Treatment Options in Oncology, 2005, 6 (5) : 357 - 365
  • [47] Systemic therapy of metastatic renal cell carcinoma
    Maute, Luise
    Bergmann, Lothar
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (07) : 466 - 469
  • [48] Renal cell carcinoma - evolution of systemic therapy
    Krzakowski, Maciej
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2007, 3 : A11 - A18
  • [49] Systemic therapy of metastatic renal cell carcinoma
    Autenrieth, M.
    Heidenreich, A.
    Gschwend, J. E.
    [J]. UROLOGE, 2006, 45 (05): : 594 - 599
  • [50] Systemic Therapy for Metastatic Renal Cell Carcinoma
    Kroog, Glenn S.
    Motzer, Robert J.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2008, 35 (04) : 687 - 701
12345